{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-116646","form_type":"8-K","ticker":"MIST","cik":"0001408443","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.939468+00:00","generated_at":"2026-06-08T04:48:32.038194+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Milestone Pharma reports Q3 2023 results; NDA submitted for etripamil in PSVT","bullets":["Cash $75.7M as of Sep 30, 2023; expected to fund operations into mid-2025.","Q3 operating loss $15.4M vs $15.0M prior year; R&D expense down to $6.7M.","NDA for etripamil (CARDAMYST) in PSVT submitted to FDA; acceptance decision by end of 2023.","Positive Phase 2 ReVeRA data for etripamil in AFib-RVR presented at AHA; Phase 3 program to start mid-2024.","Commercial expense rose to $4.4M in Q3 from $2.7M prior year, building pre-launch capabilities."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-116646","json":"https://secwatch.observer/filing/0001104659-23-116646.json","markdown":"https://secwatch.observer/filing/0001104659-23-116646.md","text":"https://secwatch.observer/filing/0001104659-23-116646.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1408443/000110465923116646/0001104659-23-116646-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1408443/000110465923116646/tm2330492d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T04:48:32.038194+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"80e47ede5df5333f72a34d8f9a40d1b7b9a3283a","claim":"Milestone Pharmaceuticals Inc. reported financial results for third quarter ended September 30, 2023.","evidence_excerpt":"On November 13, 2023, Milestone Pharmaceuticals Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2023, which also provided a clinical and corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465923116646/0001104659-23-116646-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}